QIAGEN announces the QIAcuityDx Digital PCR System, an addition to its digital PCR portfolio expanding into clinical diagnostics. QIAcuityDx streamlines clinical testing by providing precise, absolute quantitation of target DNA and RNA, supporting applications with less invasive liquid biopsies. These capabilities make it an ideal tool for monitoring cancer progression, complementing routine cancer diagnoses, which are typically performed using next generation sequencing (NGS). QIAGEN is expanding the application menu available on QIAcuityDx-System, with a new BCR::ABL assay for oncohematology planned for FDA submission. The QIAcuityDx platform is an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined 5-plex workflow within a single instrument. Capable of processing up to 4 nanoplates simultaneously, it can help reduce instrument footprint, minimize servicing needs, and limit operator time. The system’s technology enables high throughput, allows for imaging of partitions, improves precision and sensitivity, cuts processing time to 2 hours, and reduces the risk of cross-contamination. Designed for diagnostic use, the system features a user-friendly interface and comprehensive audit trail.